This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Case against Celgene over Thalomid, Revlimid should go forward, buyers argue

( March 17, 2015, 23:31 GMT | Official Statement) -- MLex Summary: A court should hear claims that drugmaker Celgene abused safety regulations and used sham patent litigation to prevent generic competitors from making versions of the costly drugs Thalomid and Revlimid, buyers of the drug said in a brief opposing Celgene's motion to dismiss. At best, Celgene's request for dismissal raises factual issues that cannot be decided early on in the case, the plaintiffs said.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections